Authors: Joon Mo Kim TaeWoo Kim Chan Yun Kim Hwang Ki Kim Ki Ho Park
Publish Date: 2015/11/18
Volume: 60, Issue: 1, Pages: 20-26
Abstract
This was a multiinstitution randomized activecontrolled openlabel parallelgroup study After a full ophthalmic and glaucoma examination a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 05 with timolol—participated in this study Among them 1 failed to meet the inclusion/exclusion criteria 10 revoked their consent to participate in the study 3 had adverse reactions and 1 had a drug adherence rate of less than 70 Ultimately a total of 95 patients—48 in the BTFC group and 47 in the 05 timolol group—completed the study The study visits took place at baseline and at 4 and 12 weeks Diurnal IOP was measured at 9 am 11 am and 5 pm during the baseline visit and the visit at 12 weeks after eyedrop instillation At each followup visit compliance was assessed Throughout the study all adverse events were recorded and monitored by the investigatorsThe average difference in IOP change measured at 11 am 12 weeks after administration between the two groups was 210 ± 259 mmHg The BTFC group had a better IOPlowering effect at all time points than did the 05 timolol group The ratio of patients whose average IOP had decreased by 20 after 4 and 12 weeks was 50 and 56 in the BTFC group respectively whereas it was 2941 and 2353 in the 05 timolol group respectively p = 0034 0001
Keywords: